|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV056291620 |
| 003 |
DE-627 |
| 005 |
20230624231003.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
220105s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.earlhumdev.2021.105509
|2 doi
|
| 028 |
5 |
2 |
|a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001621.pica
|
| 035 |
|
|
|a (DE-627)ELV056291620
|
| 035 |
|
|
|a (ELSEVIER)S0378-3782(21)00208-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 084 |
|
|
|a 44.45
|2 bkl
|
| 100 |
1 |
|
|a Bednarczuk, Nadja
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nicotine replacement therapy and e-cigarettes in pregnancy and infant respiratory outcomes
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a Nicotine replacement therapy (NRT) and e-cigarettes are recommended to pregnant women who wish to stop smoking. Albeit eliminating other harmful components of cigarettes, those alternatives still expose the developing fetus to nicotine. The lungs may be particularly vulnerable to damage by nicotine as there is widespread nicotinic-acetylcholine receptor expression in the lungs. There is, however, a paucity of information about the effect of NRT and e-cigarette use in pregnancy on infant respiratory outcomes.
|
| 700 |
1 |
|
|a Williams, Emma E.
|4 oth
|
| 700 |
1 |
|
|a Dassios, Theodore
|4 oth
|
| 700 |
1 |
|
|a Greenough, Anne
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
| 773 |
1 |
8 |
|g volume:164
|g year:2022
|g pages:0
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.earlhumdev.2021.105509
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 164
|j 2022
|h 0
|